Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury
STARRT-AKI trial design and results
Design
Multicentre randomised controlled trial
Treatment
Accelerated initiation of renal replacement therapy
Control
Standard, deferred initiation
Population
2927 analysed critically ill patients with acute kidney injury: 1465 accelerated and 1462 standard
Follow-up
90 days
Primary endpoint
Death from any cause at 90 days
Result
Among the 2927 patients in the modified intention-to-treat analysis, accelerated initiation did not reduce 90-day mortality and was associated with greater dependence on renal replacement therapy at 90 days. Adverse events occurred in 346 of 1503 (23.0%) with accelerated initiation versus 245 of 1489 (16.5%) with the standard strategy (p<0.001).
Secondary endpoints
Dependence on renal replacement therapy at 90 days, adverse events
Among critically ill patients with acute kidney injury, an accelerated renal-replacement strategy was not associated with a lower risk of death at 90 days than a standard strategy. (Funded by the Canadian Institutes of Health Research and others; STARRT-AKI ClinicalTrials.gov number, NCT02568722.).
The trial authors, in the published abstract
How it has aged
The largest trial of dialysis timing, and it makes waiting the default. Many patients randomised to the standard arm never needed dialysis at all, which is the practical argument — as with tracheostomy timing in TracMan.
Publications
Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury
Bagshaw SM, Wald R, Adhikari NKJ, et al. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med 2020 Jul 16;383(3):240-251.
No mortality reduction with accelerated initiation
More dependence on renal replacement therapy at 90 days